Crescent Biopharma, Inc. (CBIO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $13.50
- As of
Kresmion compiles this page from CBIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
CRESCENT BIOPHARMA, INC. (CBIO): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-12.
See the full CBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the CBIO dossierActive events for CBIO
- mediumEarnings below estimates
Q3-2026: Missed consensus by 23.3%, EPS $-0.90 vs $-0.7302 estimate
- medium13F: new position
SOROS FUND MANAGEMENT LLC new position in CBIO
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +61% to CBIO (2026Q2)
- mediumEarnings above estimates
Q2-2026: Beat consensus by 8.7%, EPS $-0.74 vs $-0.8109 estimate
- mediumEarnings below estimates
Q2-2025: Missed consensus by 174.2% - EPS $-4.93 vs $-1.7978 estimate
FREE, NO ACCOUNT
Every event on CBIO, as it fires
You are seeing 5 of 8 events recorded on CBIO since 2026-05-29.
The five above landed across 5 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
CBIO positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| SOROS FUND MANAGEMENT LLC FundCUSIP G2545C104 · 2026Q3 | $292K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CBIO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on CBIO
CBIO against its peers
CBIO's operating margin of -1407.5% ranks in the 21st percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.8M USD | 5.4M USD | 57 | 14 |
| Gross margin | n/a | 69.9% | n/a | 5 |
| Operating margin | -1407.5% | -94.6% | 21 | 11 |
| Net margin | -1419.6% | -113.8% | 29 | 11 |
| Return on equity | -75.8% | -58.4% | 34 | 21 |
| 1 year | 3.6% | 5.5% | 48 | 21 |
Peers (22): VALN, ZVRA, MYGN, RGNX, CAPR, EPRX, NGNE, SANA, ENTX, MNPR, FTH, OBIO, SRZN, OVID, DMAC, STTK, GYRE, MDXG, GERN, CADL, CLYM, RLMD. Left out: SLBT (no annual filing), IAM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in CBIO on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on CBIO in the last 180 days.
Upstream: SEC EDGAR filings for CBIO
Kresmion, "CRESCENT BIOPHARMA, INC. (CBIO) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/CBIO. Upstream data: SEC EDGAR filings for CBIO.
Link to this data (HTML):
<a href="https://kresmion.com/research/CBIO">CRESCENT BIOPHARMA, INC. (CBIO) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow CBIO on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to CBIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.